Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available.
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2016
At a glance
- Drugs IMC 3C5 (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly
- 29 May 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 29 May 2015 Primary endpoint has not been met (maximum tolerated dose (MTD)) according to results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 07 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.